Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580

被引:22
|
作者
Sumida, T [1 ]
Otani, H [1 ]
Kyoi, S [1 ]
Okada, T [1 ]
Fujiwara, H [1 ]
Nakao, Y [1 ]
Kido, M [1 ]
Imamura, H [1 ]
机构
[1] Kansai Med Univ, Dept Thorac & Cardiovasc Surg, Cardiovasc Res Ctr, Moriguchi, Osaka 5708507, Japan
关键词
necrosis; contractility;
D O I
10.1152/ajpheart.01183.2004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
p38 MAP kinase activation is known to be deleterious not only to mitochondria but also to contractile function. Therefore, p38 MAP kinase inhibition therapy represents a promising approach in preventing reperfusion injury in the heart. However, reversal of p38 MAP kinase-mediated contractile dysfunction may disrupt the fragile sarcolemma of ischemic-reperfused myocytes. We, therefore, hypothesized that the beneficial effect of p38 MAP kinase inhibition during reperfusion can be enhanced when contractility is simultaneously blocked. Isolated and perfused rat hearts were paced at 330 rpm and subjected to 20 min of ischemia followed by reperfusion. p38 MAP kinase was activated after ischemia and early during reperfusion (<30 min). Treatment with the p38 MAP kinase inhibitor SB-203580 (10 mu M) for 30 min during reperfusion, but not the c-Jun NH2-terminal kinase inhibitor SP-600125 (10 mu M), improved contractility but increased creatine kinase release and infarct size. Cotreatment with SB-203580 and the contractile blocker 2,3-butanedione monoxime (BDM, 20 mM) or the ultra-short-acting beta-blocker esmorol (0.15 mM) for the first 30 min during reperfusion significantly reduced creatine kinase release and infarct size. In vitro mitochondrial ATP generation and myocardial ATP content were significantly increased in the heart cotreated with SB-203580 and BDM during reperfusion. Dystrophin was translocated from the sarcolemma during ischemia and reperfusion. SB-203580 increased accumulation of Evans blue dye in myocytes depleted of sarcolemmal dystrophin during reperfusion, whereas cotreatment with BDM facilitated restoration of sarcolemmal dystrophin and mitigated sarcolemmal damage after withdrawal of BDM. These results suggest that treatment with SB-203580 during reperfusion aggravates myocyte necrosis but concomitant blockade of contractile force unmasks cardioprotective effects of SB-203580.
引用
收藏
页码:H2726 / H2734
页数:9
相关论文
共 50 条
  • [41] Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase
    Kumar, S
    Jiang, MS
    Adams, JL
    Lee, JC
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 263 (03) : 825 - 831
  • [42] Effects of SB203580, a selective inhibitor of p38 mitogen activated protein kinase, on bone resorption in cell and organ culture.
    Ranges, GE
    Bourret, L
    Woodiel, FN
    Raisz, LG
    Weaver, D
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S363 - S363
  • [43] SB203580, the p38 mitogen-activated protein kinase inhibitor blocks the inhibitory effect of β-amyloid on long-term potentiation in the rat hippocampus
    Saleshando, G
    O'Connor, JJ
    NEUROSCIENCE LETTERS, 2000, 288 (02) : 119 - 122
  • [44] Effect of p38 MAP kinases on contractility and ischemic injury in intact heart
    Cross, H. R.
    Li, M.
    Petrich, B. G.
    Murphy, E.
    Wang, Y.
    Steenbergen, Ch
    ACTA PHYSIOLOGICA HUNGARICA, 2009, 96 (03) : 307 - 323
  • [45] Contribution of p38, p44/p42 MAP kinases and protein kinase C in the cardioprotective effect of palmitoylethanolamide
    Lepicier, P
    Bouchard, JF
    Lamontagne, D
    EUROPEAN HEART JOURNAL, 2001, 22 : 51 - 51
  • [46] Role of p38 MAP Kinase Inhibitor (SB239063) and Vitamin B12 against Neuroinflammation
    Verma, Ashish Kumar
    Singh, Mamta Farswan
    Awasthi, Akanksha
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2021, 11 (01) : 94 - 98
  • [47] Myocardial protective effect of FR167653, a novel inhibitor of p38 MAP kinase in ischemia-reperfused rat heart: A role of p38 MAPK in ischemia reperfusion injury
    Alechine, AN
    Ohtake, S
    Nishimura, M
    Kagisaki, K
    Ueno, T
    Matsuda, H
    CIRCULATION, 2001, 104 (17) : 473 - 473
  • [48] Suppression of ex vivo cytokine production by SB-242235, a selective inhibitor of p38 map kinase.
    Fullerton, T
    Sharma, A
    Prabhakar, U
    Tucci, M
    Boike, S
    Davis, H
    Jorkasky, D
    Williams, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 114 - 114
  • [49] Differential regulation of mast cell cytokines by both dexamethasone and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580
    Koranteng, RD
    Swindle, EJ
    Davis, BJ
    Dearman, RJ
    Kimber, I
    Flanagan, BF
    Coleman, JW
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 137 (01): : 81 - 87
  • [50] SB203580-A Potent p38 MAPK Inhibitor Reduces the Profibrotic Bronchial Fibroblasts Transition Associated with Asthma
    Paw, Milena
    Wnuk, Dawid
    Nit, Kinga
    Bobis-Wozowicz, Sylwia
    Szychowski, Rafal
    Slusarczyk, Alicja
    Madeja, Zbigniew
    Michalik, Marta
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)